153 related articles for article (PubMed ID: 37042147)
1. [Consistency comparison of programmed cell death 1-ligand 1 in different immuno-histochemical staining methods].
Li D; DI JT; Xiong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):339-342. PubMed ID: 37042147
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G
Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194
[TBL] [Abstract][Full Text] [Related]
3. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
[TBL] [Abstract][Full Text] [Related]
4. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
[TBL] [Abstract][Full Text] [Related]
5. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
[TBL] [Abstract][Full Text] [Related]
7. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970
[TBL] [Abstract][Full Text] [Related]
8. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
[TBL] [Abstract][Full Text] [Related]
9. High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples.
Zhang W; Cao Z; Gao C; Huang Y; Wu C; Zhang L; Hou L
Transl Cancer Res; 2020 Oct; 9(10):5819-5828. PubMed ID: 35117196
[TBL] [Abstract][Full Text] [Related]
10. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
[No Abstract] [Full Text] [Related]
11. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
12. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
[TBL] [Abstract][Full Text] [Related]
13. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH
Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
[TBL] [Abstract][Full Text] [Related]
17. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform.
Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW
J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
[TBL] [Abstract][Full Text] [Related]
19. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.
Lawson NL; Dix CI; Scorer PW; Stubbs CJ; Wong E; Hutchinson L; McCall EJ; Schimpl M; DeVries E; Walker J; Williams GH; Hunt J; Barker C
Mod Pathol; 2020 Apr; 33(4):518-530. PubMed ID: 31558782
[TBL] [Abstract][Full Text] [Related]
20. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
